Overview

Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients

Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
Open-label, single-center, single-treatment group, baseline-controlled (for safety) study of the safety and biodistribution of Technetium Tc 99m EC20 in four normal subjects and four subjects with known or suspected ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Endocyte
Treatments:
Technetium Tc 99m-ethylenedicysteine